FDA panel to mull DTC changes

Brace yourselves: An FDA advisory committee meets today to hash over the possibility of putting a side-effects hotline number in every DTC television commercial. The meeting comes at a time when drug ads are under increased scrutiny; just last week, Congress heard testimony about the ads, including expert assessment that commercials are engineered to play down warnings and emphasize benefits. One researcher said she'd found that 80 percent of TV viewers could recall drug benefits mentioned in commercials, but only 20 percent remembered side effects.

Print ads, you'll recall, already include FDA contact info so patients can report side effects. Some lawmakers and consumer groups say adding that info to TV ads as well would help regulators catch drug safety problems sooner.

- see the item at Pharmalot
- check out the Associated Press story

ALSO: A stent skeptic assails DTC advertising for Johnson & Johnson's Cypher product in the New England Journal of Medicine, saying the TV commercials cross an ethical line; J&J says the ad is balanced and points viewers to sources of more detailed information. Report

Free Webinar

What could you do with real-time supply chain information at your fingertips?

Interested in complete supply chain real-time data visibility? Unlock productivity with digital workflows, manage plants inventory with real-time supply chain information and enable faster decision-making with data visualization with pci | bridge. Register today!

Suggested Articles

Incyte and Novartis' Jakafi is eying a nod in chronic graft vs. host disease—and it may just have the data to get it done.

With a slate of vaccine authorizations on the horizon, vaccine execs from a trio of leading shot makers are looking at distribution hurdles ahead.

News of an FDA plant inspection for a Macrogenics drug boosted investor confidence in BMS' ability to meet its year-end deadline for liso-cel.